CD BioGlyco has been specializing in Carbohydrate-based Vaccine Development for many years, building a comprehensive Glyco™ Vaccine Development Platform. Based on this platform, we provide our clients with a professional Tumor-Associated Glycolipid Antigen Production Service, in which our tumor-associated GM1 ganglioside antigen production service has been recognized by many clients. The following are the details of our service:
The method we usually use is to condense Gal-Neu5Ac with N-acetylcysteine (NAcCys) to obtain the tripeptide unit NAcCys-Gal-Neu5Ac. N-acetylneuraminic acid (Neu5Ac) is then cyclized with D-galactose to obtain the disaccharide unit The tripeptide unit NAcCys-Gal-Neu5Ac is then subjected to a Michael addition reaction with di-vinyl glycerol (DVG) to form tetraene acid (TEA). Finally, the TEA is subjected to a deprotecting group reaction and selective oxidation to obtain a GM1 analog, and then after deprotecting the hydroxyl group and sulfation steps, the synthetic GM1 Ganglioside is obtained.
We utilize cell culture techniques, such as using tumor cell lines or cell lines transfected with specific genes. These cell lines can express GM1 synthesis-related enzymes and produce the tumor-associated GM1 ganglioside antigen. When the cells are cultured, media and nutrients are added to them to promote cell growth and metabolite synthesis.
Extracting GM1 gangliosides from natural sources is a method we commonly employ. The extraction process usually involves steps such as cell fragmentation, solvent extraction, and chromatographic separation.
We also provide you with subsequent anti-tumor vaccine development services based on GM1 ganglioside antigen, which combines tumor-associated GM1 ganglioside antigen with appropriate immune adjuvants to investigate its effect on tumor immunotherapy by stimulating the body to produce specific antibody responses and T-cell responses.
Fig.1 Applications of GM1 ganglioside antigen. (CD BioGlyco)
DOI: 10.1002/cbic.200200540
Journal: ChemBioChem
Abstract: This article is centered on the large-scale in vivo synthesis of the carbohydrate moieties of ganglioside GM1 using metabolically engineered modified Escherichia coli. Researchers altered the gene expression levels of metabolic pathways in E. coli to achieve the production of carbohydrate molecules of ganglioside GM1.
Method: GM1 can be synthesized effectively through the high-cell-density cultivation of an E. coli strain that enhances the expression of genes responsible for glycosyltransferases and sugar-nucleotide synthases specific to GM1 production. The strain TA02, engineered to produce GM1 oligosaccharide, exhibited overexpression of β-1,3 galactosyltransferase genes. During the cultivation of this strain in the presence of glycerol, it was observed that externally provided lactose and sialic acid were efficiently absorbed into the cytoplasm and subsequently transformed into GM2 oligosaccharides.
Fig.2 Structure of the GM1 ganglioside. (Aureli, et al., 2016)
It has been discovered that certain tumor cells exhibit an increased expression of GM1 ganglioside antigen on the surface. The expression of this GM1 ganglioside antigens associated with tumors can be detected in various malignant tumor types, including but not limited to pancreatic, gastric, colorectal, and ovarian cancers. Furthermore, there is a significant association between the overexpression of GM1 ganglioside antigen and the advancement and progression of tumors.
Based on our professional scientists, CD BioGlyco is competent enough to provide GM1 ganglioside antigen production services based on various methods. Additionally, we provide valuable support through subsequent structure identification and data interpretation services. If you require further information, please do not hesitate to contact us.
References
